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Introduction
Drug delivery systems offer the potential to enhance the
therapeutic index of anticancer agents, either by increasing
the drug concentration in tumor cells and/or by decreasing
the exposure in normal host tissues. This commentary will
discuss some of the recent trends in liposome-based drug
delivery systems for breast cancer therapy.
Solid tumors such as breast cancer have historically pro-
vided many challenges to systemic therapy. Theoretical
barriers to drug penetration in solid tumors include hetero-
geneous vascular supply and high interstitial pressures
within tumor tissue, particularly in necrotic zones. Delivery
systems can even exacerbate these problems due to the
slow diffusion of macromolecular agents through tumor
tissue.
However, delivery systems have been developed to exploit
a feature of tumor microphysiology often referred to as the
‘enhanced permeability and retention’ effect [1]. This
effect is a consequence of the dysregulated nature of
tumor angiogenesis, which characteristically involves
structural and physiologic defects leading to hyperperme-
ability. Macromolecular agents with highly restricted
volumes of distribution and the capacity for greatly pro-
longed circulation will preferentially extravasate from these
abnormal vessels and accumulate in tumor tissue. The
leading examples of such ‘passively targeted’ agents
include long circulating liposomal drugs.
Delivery of anthracyclines
Anthracyclines exemplify the case of potent anticancer
activity that is constrained by highly problematic systemic
toxicities. For this reason, the most studied drug delivery
applications in oncology have involved anthracyclines to
preserve or to enhance efficacy against tumor cells while
limiting exposure to critical target sites such as
myocardium and bone marrow.
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Abstract
Drug delivery systems can in principle provide enhanced efficacy and/or reduced toxicity for anticancer
agents. Long circulating macromolecular carriers such as liposomes can exploit the ‘enhanced
permeability and retention’ effect for preferential extravasation from tumor vessels. Liposomal
anthracyclines have achieved highly efficient drug encapsulation, resulting in significant anticancer
activity with reduced cardiotoxicity, and include versions with greatly prolonged circulation such as
liposomal daunorubicin and pegylated liposomal doxorubicin. Pegylated liposomal doxorubucin has
shown substantial efficacy in breast cancer treatment both as monotherapy and in combination with
other chemotherapeutics. Additional liposome constructs are being developed for the delivery of other
drugs. The next generation of delivery systems will include true molecular targeting; immunoliposomes
and other ligand-directed constructs represent an integration of biological components capable of
tumor recognition with delivery technologies.
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Anthracyclines have been encapsulated in a number of
liposomal constructs. Current versions utilize ion trap-
ping methods to achieve extremely efficient loading of
doxorubicin or daunorubicin within the aqueous interior of
unilamellar (single bilayer) liposomes, reaching 104 drug
molecules per liposome particle. Liposome-encapsulated
doxorubicin (TLC D-99, Myocet™; Elan Pharmaceuticals,
Inc., Cedar Knolls, NJ, USA) was developed as a multiple
vial kit, with individual vials containing moderately sized
(~190 nm) liposomes, lyophilized doxorubicin, and citric
acid buffer. The components are mixed at point of care,
resulting in highly efficient (>99%) loading of doxorubicin
into the liposomes. Myocet™ provides a limited degree of
prolonged circulation as compared with free drug.
However, the liposome encapsulation significantly alters
the biodistribution of doxorubicin, resulting in some reduc-
tion in toxicities.
A randomized trial of Myocet™ versus doxorubicin, with
both in combination with cyclophosphamide for first-line
treatment of metastatic breast cancer, showed compara-
ble response rates for the two regimens. However,
Myocet™ was associated with a decreased frequency of
cardiotoxicity and neutropenia [2]. While the decrease in
toxicities was clearly shown, there remains controversy as
to whether Myocet™ has demonstrated equivalent efficacy
to doxorubicin [3].
Liposomes capable of markedly prolonged circulation and
enhanced tumor accumulation have been developed, using
a series of modifications to liposome structure that act to
retard uptake by mononuclear phagocytes. Liposomal
daunorubicin (DaunoXome®; Gilead Sciences, Inc., Forest
City, CA, USA) provides extended circulation with its very
small size (~45 nm) and its rigid bilayer, and it is clearly
active against Kaposi’s sarcoma and other tumors [4].
Pegylated liposomal doxorubicin (Doxil®, Caelyx®; Alza
Pharmaceuticals, San Bruno, CA, USA) has achieved the
most prolonged circulation to date, with a terminal half-life
of 55 hours in humans. These are small (~100 nm) and
rigid liposomes, onto which a polymeric coat of polyethyl-
ene glycol has been grafted. These pegylated (also
referred to as sterically stabilized or ‘Stealth’) liposomes
display inhibited interaction with plasma proteins and
mononuclear phagocytes, and they consequently display
greatly prolonged circulation time.
These pharmacokinetics in turn facilitate accumulation in
tumor tissue, which has been demonstrated in assays of
tumor biopsies in Kaposi’s sarcoma [5] and skeletal
metastases of breast cancer [6]. Furthermore, the altered
biodistribution and pharmacokinetics substantially mitigate
many of the typical toxicities of bolus doxorubicin adminis-
tration, such as nausea and alopecia, while inducing alter-
nate toxicities. The most notable of these is palmar–
plantar erythrodysesthesia (‘hand–foot syndrome’), which
has generally been associated with continuous infusion
schedules of doxorubicin rather than bolus administration.
Palmar–plantar erythrodysesthesia is the usual dose-
limiting toxicity of Doxil®, and it renders problematic any
substantial dose escalation that liposome delivery might
otherwise provide.
Doxil® has shown efficacy against a number of solid tumor
types, including Kaposi’s sarcoma and refractory ovarian
cancer. In metastatic breast cancer, phase II trials of
Doxil® monotherapy as first-line or second-line treatment
have observed response rates of 31% [7]. Ongoing phase
III studies include a direct comparison of Doxil® versus
doxorubicin in metastatic breast cancer. Polychemother-
apy studies involving Doxil® have included Doxil® plus
cyclophosphamide as first-line treatment of metastatic
breast cancer, which was associated with a response rate
of 65% [8]. Doxil® has also been tested in combination
with gemcitabine [9] or docetaxel [10], with these regi-
mens showing good tolerability and activity.
The biodistribution of liposomes can reduce the cardio-
toxic effects of anthracyclines. As already mentioned,
Myocet™ has demonstrated reduced cardiotoxicity in com-
bination with cyclophosphamide. A study of Doxil® in
which cardiac biopsies were performed in 10 treated
patients observed significantly less histopathologic
evidence of myocardial injury than in matched patients
receiving somewhat higher doses of free doxorubicin [11].
Anthracycline cardiotoxicity has attracted renewed interest
with the advent of trastuzumab, a recombinant humanized
mAb against the product of the HER2 (erbB2, neu) proto-
oncogene [12]. Trastuzumab in combination with
doxorubicin or epirubicin is highly efficacious but is asso-
ciated with an extremely high frequency of cardiotoxicity
[12]. For this reason, clinical trials are evaluating the com-
bination of trastuzumab with liposomal anthracyclines,
including two separate trials with Myocet™ and Doxil®.
Polymer-based drug delivery represents another strategy to
favorably alter the pharmacokinetics and biodistribution of
derivatized drugs. One example is PK-1, a conjugate of the
water-soluble, acrylamide-based, copolymer N-(2-hydroxy-
propyl)methacrylamide and doxorubicin [13]. Polymer-
based anthracyclines have not achieved the same degree
of prolonged circulation as sterically stabilized liposomal
doxorubicin. However, their circulation does significantly
surpass that of free doxorubicin, resulting in tumor accumu-
lation via the ‘enhanced permeability and retention’ effect.
The optimal role for liposomal anthracyclines in breast
cancer treatment remains to be determined. The most
prominent feature of these agents has been a decrease in
many of the toxicities of anthracycline therapy rather than
an increase in potency. Hence, liposomal anthracyclines(particularly Doxil®, based on its pharmacology and exist-
ing clinical data) could be considered for inclusion in first-
line or second-line regimens in place of standard
anthracyclines. Greater utility may be achieved via molecu-
lar targeting for increased potency (discussed later).
Liposomal delivery of other drugs
The most active drugs against breast cancer are currently
the anthracyclines and taxanes (paclitaxel and docetaxel).
Strategies for the delivery of taxanes are under active
investigation to increase tumor exposure and/or to reduce
adverse effects such as neurotoxicity, edema, asthenia,
and alopecia. In addition, special issues with the taxanes
provide further rationale for application of delivery
systems. Both paclitaxel and docetaxel are poorly soluble
in aqueous solutions, and have consequently been formu-
lated with vehicles Cremaphor EL and polysorbate 80
(TWEEN), respectively. These formulations are highly aller-
genic, require extensive premedication, and are responsi-
ble for most of the acute toxicities observed with taxane
therapy, rather than the taxanes themselves. Delivery
strategies in clinical trials include liposome-encapsulated
paclitaxel [14] and poly(L-glutamic acid)–paclitaxel, a
polymer conjugate [15].
Other applications for delivery systems in breast cancer
include approved chemotherapy drugs such as vinca alka-
loids, platinums, and camptothecins. In each case, it is pos-
sible that delivery systems such as liposomes or polymers
could improve pharmacokinetics, could increase tumor
accumulation, and/or could reduce limiting toxicities.
While delivery systems for standard anticancer com-
pounds may increase their clinical utility, there is also
intense interest in developing delivery strategies for novel
anticancer agents that cannot be used by themselves as
drugs. Delivery systems can potentially overcome many
common pharmacologic problems such as those involving
solubility, in vivo stability, pharmacokinetics, tumor uptake,
and toxicity. The increasing repertoire of sophisticated
delivery systems may thus allow new classes of potent
anticancer agents to reach clinical application. This
includes not only drug delivery, but also liposome-derived
systems for nucleic acid-based agents, such as antisense
oligonucleotides and gene therapy constructs.
Towards molecularly targeted drug delivery
As discussed, currently approved liposomal drug delivery
systems provide stable formulation, provide improved
pharmacokinetics, and provide a degree of ‘passive’ or
‘physiological’ targeting to tumor tissue. However, these
carriers do not directly target tumor cells. The design mod-
ifications that protect liposomes from undesirable interac-
tions with plasma proteins and cell membranes, and which
contrast them with reactive carriers such as cationic lipo-
somes, also prevent interactions with tumor cells. Instead,
after extravasation into tumor tissue, liposomes remain
within tumor stroma as a drug-loaded depot. Liposomes
eventually become subject to enzymatic degradation
and/or phagocytic attack, leading to release of drug for
subsequent diffusion to tumor cells. The next generation of
drug carriers under development features direct molecular
targeting of cancer cells via antibody-mediated or other
ligand-mediated interactions.
Immunoliposomes, in which mAb fragments are conju-
gated to liposomes, represent a strategy for molecularly
targeted drug delivery (for a review, see [16]). Anti-HER2
immunoliposomes have been developed with either Fab′
or scFv fragments linked to long circulating liposomes
[17]. In preclinical studies, anti-HER2 immunoliposomes
bound efficiently to and internalized in HER2-overexpress-
ing cells, resulting in efficient intracellular delivery of
encapsulated agents [17–20]. Anti-HER2 immuno-
liposomes loaded with doxorubicin displayed potent and
selective anticancer activity against HER2-overexpressing
tumors, including significantly superior efficacy versus all
other treatments tested (free doxorubicin, liposomal
doxorubicin, free mAb [trastuzumab], and combinations of
trastuzumab plus doxorubicin or liposomal doxorubicin)
[21]. Anti-HER2 immunoliposomes are currently under-
going scale up for clinical studies.
The immunoliposome approach offers a number of theoreti-
cal advantages as compared with other antibody-based
strategies. Anti-HER2 immunoliposome delivery of doxoru-
bicin may circumvent the prohibitive cardiotoxicity associ-
ated with combined trastuzumab plus doxorubicin
treatment. Anti-HER2 immunoliposomes can be constructed
using scFv that, unlike trastuzumab, lack antiproliferative
activity, are incapable of antibody-dependent  cellular cyto-
toxicity, and require threshold levels of HER2 expression
for delivery [20,21]. In contrast to drug immunoconjugates,
which consist of a small number of drugs (typically <10
drugs per mAb) directly coupled via linkers to selected
residues on the mAb, immunoliposomes exploit the expo-
nentially greater capacity of drug-loaded liposomes (up to
104 drugs per liposome). Immunoliposomes also appear to
be nonimmunogenic and capable of long circulation even
with repeated administration.
Antibody-based targeting is also being developed in
conjunction with polymer systems. Similarly, ligand-based
targeting using growth factors, hormones, vitamins (e.g.
folate), peptides or other specific ligands is being pursued
in conjunction with both liposomes and polymers.
Breast cancer involving the chest wall
A special problem in the management of advanced breast
cancer is that of chest wall recurrence/metastasis, which
is typically highly morbid and difficult to treat. Photo-
dynamic therapy, in which systemically administered
Available online http://breast-cancer-research.com/content/4/3/095photosensitive compounds are activated by an external
light source, can be considered a related strategy to drug
delivery and is under investigation for the treatment of
superficial breast tumors.
In a multimodality strategy, hyperthermia (which is cur-
rently used to enhance the efficacy of external beam radia-
tion for chest wall metastasis) has been used to modulate
delivery of liposomal drugs. In animal models, the applica-
tion of hyperthermia to subcutaneous tumors concomitant
with or prior to intravenous administration of long circulat-
ing liposomes results in a marked increase in liposome
accumulation within tumor tissue [22,23]. The mechanism
for this hyperthermia-enhanced liposome delivery appears
to be via heat-induced changes in vascular permeability
and microcirculatory dynamics, which further facilitate lipo-
some extravasation from tumor vessels.
In a phase I/II clinical trial of metastatic breast cancer
involving the chest wall, sequential hyperthermia followed
by pegylated liposomal doxorubicin (Doxil®) was very well
tolerated and produced objective responses in the major-
ity of chest wall tumors [24]. It was notable that all
patients had extensive prior treatment, and most had
recurred or progressed after radiation and multiple
chemotherapy regimens. Hyperthermia can also be used
in conjunction with thermosensitive liposomes, which are
being developed for heat-triggered release of encapsu-
lated drug in tumor tissue [25].
Conclusions
Drug delivery systems are designed to stably and effi-
ciently carry anticancer agents to tumor sites. This has
been accomplished with some success by liposomal ver-
sions of anthracyclines. Current liposomal anthracyclines
provide improved pharmacokinetics, provide reduced toxi-
cities to a number of organ sites, and provide potentially
increased tumor uptake. The next generation of delivery
systems in development combine these features with
tumor cell recognition, and include antibody-targeted and
cell-internalizing systems. Such systems will enable drug
delivery to move beyond pharmacokinetic-driven and
biodistribution-driven mechanisms to true molecular tar-
geting. This trend can also be viewed as an integration of
biological therapeutics and drug delivery technologies. It
is probable that such integrated approaches will include
biologically targeted delivery systems for small molecule
drugs as well as for biological agents with anticancer
activity, and will be an increasingly important theme in the
development of new treatments of breast cancer.
Acknowledgements
This work was supported by grants from the National Cancer Institute
Specialized Programs of Research Excellence (SPORE) in Breast Cancer
(P50-CA 58207-01), from the Department of Defense Breast Cancer
Research Program (DAMD17-94-J-4195 and DAMD17-98-1-8288), and
from the California Breast Cancer Research Program (2CB-0250).
References
1. Matsumura Y, Maeda H: A new concept for macromolecular
therapeutics in cancer chemotherapy: mechanism of
tumoritropic accumulation of proteins and the antitumor
agent SMANCS. Cancer Res 1986, 6:193-210.
2. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A,
Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K,
Tkaczuk K, Park YC, Lee LW: Reduced cardiotoxicity and pre-
served antitumor efficacy of liposome-encapsulated doxoru-
bicin and cyclophosphamide compared with conventional
doxorubicin and cyclophosphamide in a randomized, multi-
center trial of metastatic breast cancer. J Clin Oncol 2001,
19:1444-1454.
3. Williams G, Cortazar P, Pazdur R: Developing drugs to
decrease the toxicity of chemotherapy. J Clin Oncol 2001, 19:
3439-3441.
4. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von
Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick
MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME: Ran-
domized phase III trial of liposomal daunorubicin versus dox-
orubicin, bleomycin, and vincristine in AIDS-related Kaposi’s
sarcoma. J Clin Oncol 1996, 14:2353-2364.
5. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J,
Newman M, Amantea MA, Kaplan LD: Doxorubicin encapsu-
lated in liposomes containing surface-bound polyethylene
glycol: pharmacokinetics, tumor localization, and safety in
patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol
1996, 36:55-63.
6. Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E,
Gabizon A: Selective delivery of doxorubicin to patients with
breast carcinoma metastases by stealth liposomes. Cancer
1999, 86:72-78.
7. Ranson MR, Carmichael J, O’Byrne K, Stewart S, Smith D, Howell
A: Treatment of advanced breast cancer with sterically stabi-
lized liposomal doxorubicin: results of a multicenter phase II
trial. J Clin Oncol 1997, 15:3185-3191.
8. Silverman P, Overmoyer B, Holder L, Tripathy D, Marrs N, Sharp-
ington T: Doxil and intravenous cyclophosphamide as first line
therapy for patients with metastatic breast cancer (MBC):
interim results of an ongoing pilot trial [abstract]. Proc Am
Soc Clin Oncol 1999, 18:115a.
9. Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FL, Theriault RL,
Rosales MM, Booser D, Murray JL, Bast RC Jr, Hortobagyi GN:
Phase I study of stealth liposomal doxorubicin in combination
with gemcitabine in the treatment of patients with metastatic
breast cancer. J Clin Oncol 2001, 19:1716-1722.
10. Sparano JA, Malik U, Rajdev L, Sarta C, Hopkins U, Wolff AC:
Phase I trial of pegylated liposomal doxorubicin and doc-
etaxel in advanced breast cancer. J Clin Oncol 2001, 19:3117-
3125.
11. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B,
Patek A, Martin FJ: The use of cardiac biopsy to demonstrate
reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients
treated with pegylated liposomal doxorubicin. Ann Oncol
1998, 9:711-716.
12. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V,
Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
Baselga J, Norton L: Use of chemotherapy plus a monoclonal
antibody against HER2 for metastatic breast cancer that over-
expresses HER2. N Engl J Med 2001, 344:783-792.
13. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R,
Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier
D, Frigerio E, Cassidy J: Phase I clinical and pharmacokinetic
study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer
doxorubicin]: first member of a new class of chemotherapeu-
tic agents–drug–polymer conjugates. Cancer Research Cam-
paign Phase I/II Committee. Clin Cancer Res 1999, 5:83-94.
14. Cabanes A, Briggs KE, Gokhale PC, Treat JA, Rahman A: Com-
parative in vivo studies with paclitaxel and liposome-encap-
sulated paclitaxel. Int J Oncol 1998, 12:1035-1040.
15. Li C, Price JE, Milas L, Hunter NR, Ke S, Yu DF, Charnsangavej C,
Wallace S: Antitumor activity of poly(L-glutamic acid)-
paclitaxel on syngeneic and xenografted tumors. Clin Cancer
Res 1999, 5:891-897.
16. Park JW, Hong K, Kirpotin DB, Papahadjopoulos D, Benz CC:
Immunoliposomes for cancer treatment. Adv Pharmacol 1997,
40:399-435.
Breast Cancer Research    Vol 4 No 3 Park17. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C,
Shalaby R, Kotts C, Wood WI, Papahadjopoulos D, Benz CC:
Development of anti-p185HER2 immunoliposomes for cancer
therapy. Proc Natl Acad Sci USA 1995, 92:1327-1331.
18. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz
CC, Papahadjopoulos D: Sterically stabilized anti-HER2
immunoliposomes: design and targeting to human breast
cancer cell in vitro. Biochemistry 1997, 36:66-75.
19. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D,
Benz CC: Anti-HER2 immunoliposomes for targeted therapy
of human tumors. Cancer Lett 1997, 118:153-160.
20. Park JW, Kirpotin D, Hong K, Shalaby R, Shao Y, Nielsen UB,
Marks JD, Papahadjopoulos D, Benz CC: Tumor targeting using
anti-HER2 immunoliposomes. J Control Release 2001, 74:95-
113.
21. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J,
Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D,
Benz CC: Anti-HER2 immunoliposomes: enhanced anticancer
efficacy due to targeted delivery. Clin Cancer Res 2002,
8:1172-1181.
22. Park JW, Valente N, Stauffer P, Diederich C, Kirpotin D, Leung A,
Sneed P: Phase I/II study of sequential hyperthermia + Doxil®
for the treatment of breast cancer metastatic to the chest wall
[abstract]. Proc Am Soc Clin Oncol 2000, 19:90a.
23. Matteucci ML, Anyarambhatla G, Rosner G, Azuma C, Fisher PE,
Dewhirst MW, Needham D, Thrall DE: Hyperthermia increases
accumulation of technetium-99m-labeled liposomes in feline
sarcomas. Clin Cancer Res 2000, 6:3748-3755.
24. Park JW, Stauffer P, Diederich C, Colbern G, Lozner A, Kirpotin
D, Rugo H, Valente N, Sneed P: Hyperthermia (HT) + doxil sig-
nificantly enhances drug delivery and efficacy in metastatic
breast cancer of the chest wall (CW): a phase I/II study
[abstract]. Proc Am Soc Clin Oncol 2001, 20:47a.
25. Needham D, Anyarambhatla G, Kong G, Dewhirst MW: A new
temperature-sensitive liposome for use with mild hyperther-
mia: characterization and testing in a human tumor xenograft
model. Cancer Res 2000, 60:1197-1201.
Available online http://breast-cancer-research.com/content/4/3/095